You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
盤中異動 | 藥明生物盤中下跌5%,報於77.65港元
uSMART盈立智投 07-25 10:09

2022年7月25日10時9分,藥明生物(HK02269)盤中下跌5%,報於77.65港元,成交額達4.24億港元,換手率達到0.1%。

7月20日訊,藥明生物(02269.HK)今早股價抽上,一度彈高近5.8%,最新上揚近4.8%報81.25元。就藥明生物昨發今年上半年盈喜,預期上半年錄得收益按年增長61%至63%;公司利潤按年增長36%至38%,並料公司非國際財務報告準則經調整純利將增長58%至60%。瑞信發表報告表示藥明生物今年上半年收入及盈利均優於市場預期,料可推動股價表現。

7月20日,瑞信:重申藥明生物(02269)“跑贏大市”評級,目標價110港元。7月20日,國盛證券:維持藥明生物(02269)“買入”評級,六大驅動力助推快速發展。7月20日,高盛:維持藥明生物(02269)“買入”評級,目標價升至117港元。

最新的財務數據顯示,公司於2021年4季度,營業收入102.9億人民幣,淨利潤35.09億人民幣;營業收入同比增加83.35%,毛利潤同比增加90.05%,淨利潤同比增加107.28%。

盈立趨勢長盈模型最近一次交易信號,2022年7月11日出現觀望信號,觸發價格爲77.05港元(信號僅供參考)。

uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account